- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
INmune Bio Inc (INMB)
INmune Bio Inc stock price live, this page displays NASDAQ INMB stock exchange data. View the INMB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the INmune Bio Inc real time stock price chart below.
What Is the INmune Bio Inc Stock Price Today?
The INmune Bio Inc stock price today is 1.59.
What Is the Stock Symbol for INmune Bio Inc?
The stock symbol for INmune Bio Inc is "INMB."
What Stock Exchange Does INmune Bio Inc Trade On?
INmune Bio Inc is listed and trades on the NASDAQ stock exchange.
Is INmune Bio Inc a Good Stock to Buy?
Determining whether INmune Bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INMB quote. (ISIN: US45782T1051)
What Is the INmune Bio Inc Stock Price Today?
The INmune Bio Inc stock price today is 1.59.
What Is the Stock Symbol for INmune Bio Inc?
The stock symbol for INmune Bio Inc is "INMB."
What Stock Exchange Does INmune Bio Inc Trade On?
INmune Bio Inc is listed and trades on the NASDAQ stock exchange.
Is INmune Bio Inc a Good Stock to Buy?
Determining whether INmune Bio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INMB quote. (ISIN: US45782T1051)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.51
1.60
52 wk Range
1.38
11.64
INMB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.511.60
52 wk Range
1.3811.64
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
INMB Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
5.25
Upside
+230.19%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Form 424B5 INmune Bio Inc For: 22 December
- Investing.com
- Form 424B5 INmune Bio Inc For: 22 December
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral
INmune Bio Inc Company Profile
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INmune Bio Inc Earnings Call Summary for Q3/2025
- INmune Bio reported Q3 2025 EPS of -$0.24, beating forecasts by 27.27%, though stock dipped 1.65% to $1.79 in aftermarket trading
- Net loss reduced to $6.5M from $12.1M YoY, with R&D expenses down to $4.9M from $10.1M; cash reserves of $27.7M sufficient until Q4 2026
- Company plans to file MAA for Cordstrom (RDEB treatment) in UK by Q2 2026 and scheduled FDA end of Phase 2 meeting for EXPRO (Alzheimer's) in Q1 2026
- CEO David Moss positioned Cordstrom as 'potentially one of the first systemic treatments for RDEB,' highlighting the company's innovative therapeutic approach
Last Updated: 2025-10-30, 05:46 p/m
Read Full TranscriptCompare INMB to Peers and Sector
Metrics to compare | INMB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINMBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.8x | −1.8x | −0.6x | |
PEG Ratio | −0.24 | −0.02 | 0.00 | |
Price/Book | 1.6x | 1.6x | 2.6x | |
Price / LTM Sales | 834.8x | 114.4x | 3.4x | |
Upside (Analyst Target) | 252.6% | 263.8% | 44.4% | |
Fair Value Upside | Unlock | 21.1% | 6.1% | Unlock |
Analyst Ratings
3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.25
(+230.19% Upside)
Earnings
Latest Release
Oct 30, 2025
EPS / Forecast
-0.24 / -0.33
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the INmune Bio (INMB) Stock Price Today?
The INmune Bio stock price today is 1.59
What Stock Exchange Does INmune Bio Trade On?
INmune Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for INmune Bio?
The stock symbol for INmune Bio is "INMB."
What Is the INmune Bio Market Cap?
As of today, INmune Bio market cap is 42.00M.
What Is INmune Bio's Earnings Per Share (TTM)?
The INmune Bio EPS (TTM) is -2.11.
When Is the Next INmune Bio Earnings Date?
INmune Bio will release its next earnings report on Feb 26, 2026.
From a Technical Analysis Perspective, Is INMB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has INmune Bio Stock Split?
INmune Bio has split 0 times.
How Many Employees Does INmune Bio Have?
INmune Bio has 18 employees.
What is the current trading status of INmune Bio (INMB)?
As of Jan 31, 2026, INmune Bio (INMB) is trading at a price of 1.59, with a previous close of 1.56. The stock has fluctuated within a day range of 1.51 to 1.60, while its 52-week range spans from 1.38 to 11.64.
What Is INmune Bio (INMB) Price Target According to Analysts?
The average 12-month price target for INmune Bio is USD5.25, with a high estimate of USD8 and a low estimate of USD2. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +230.19% Upside potential.
What Is the INMB After Hours Price?
INMB's last after hours stock price is 1.55, the stock has decreased by -0.04, or -2.52%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.